Pharming Group (Pharming Group) Cash-to-Debt

: 1.24 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pharming Group's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.24.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pharming Group could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Pharming Group's Cash-to-Debt or its related term are showing as below:

PHAR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.47 Med: 1.24 Max: 21.5
Current: 1.24

During the past 13 years, Pharming Group's highest Cash to Debt Ratio was 21.50. The lowest was 0.47. And the median was 1.24.

PHAR's Cash-to-Debt is ranked worse than
74.51% of 1538 companies
in the Biotechnology industry
Industry Median: 6.745 vs PHAR: 1.24

Pharming Group Cash-to-Debt Historical Data

The historical data trend for Pharming Group's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pharming Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1.28

1.27

1.19

1.24

Pharming Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																1.24	1.08	1.13	1.21	1.24

Competitive Comparison

For the Biotechnology subindustry, Pharming Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Pharming Group's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pharming Group's Cash-to-Debt falls into.

Pharming Group Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pharming Group's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	213.424	/	(5.44	+	166.105)
	=	1.24

Pharming Group's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	213.424	/	(5.44	+	166.105)
	=	1.24

Pharming Group (NAS:PHAR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pharming Group Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pharming Group's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group (Pharming Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PHGUF:USA PHARM:Netherlands PHARMa:UK 0QCO:UK PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.